PTO/SB/31 (06-09)

Approved for use through 07/31/2009. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.					
1	NOTICE OF ADDEAU FROM THE EXAMINED TO	Docket Number (Optional)			
NOTICE OF APPEAL FROM THE EXAMINER TO THE BOARD OF PATENT APPEALS AND INTERFERE			33712P1		
to the	by certify that this correspondence is being facsimile transmitted USPTO or deposited with the United States Postal Service with ent postage as first class mail in an envelope addressed to	In re Application of Ashish A. Patel, et al.			
"Commissioner for Patients, P.O. Box 1450, Alexandria, VA 22313- 1450" [37 CFR 1.8(a)] July 17, 2009		Application Number Filed 2004-03-31			
Signature /J. David Gonce/		For Bilayer Tablet Comprising an Antihistamine and a Decongestant			
- Signaturo_		Art Unit		Examiner	
Typed or printed J. David Gonce		1611		Kyle A. Purdy	
Applicant hereby appeals to the Board of Patent Appeals and Interferences from the last decision of the examiner.					
The fee for this Notice of Appeal is (37 CFR 41.20(b)(1))			\$ <u>540.00</u>		
Applicant claims small entity status. See 37 CFR 1.27. Therefore, the fee shown above is reduced by half, and the resulting fee is:					
A check in the amount of the fee is enclosed.					
	Payment by credit card. Form PTO-2038 is attached.				
The Director has already been authorized to charge fees in this application to a Deposit Account.					
The Director is hereby authorized to charge any fees which may be required, or credit any overpayment to Deposit Account No. 122355					
	A petition for an extension of time under 37 CFR 1.136(a) (PTO/SB/22) is enclosed.				
WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.					
I am the					
	applicant/inventor.	/J. Da	vid Gonce/		
ΙĒ	assignee of record of the entire interest. See 37 CFR 3.71. Statement under 37 CFR 3.73(b) is enclosed. (Form PTO/SB/96)	.I Da	vid Gonce	Signature	
-		Typed or printed name			
	attorney or agent of record. Registration number		865-546-4305		
		Telephone number			
☑	attorney or agent acting under 37 CFR 1.34. Registration number if acting under 37 CFR 1.34. 47,601	July	17, 2009		
1	regulation number is using under or OTV 1.04.			Date	
NOTE: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required. Submit multiple forms if more than one signature is required, see below*.					

This collection of information is required by 20 CFR 41.31. The information is required to obtain or rotatin a benefit by the public which is to fise fant by the USPTO to process) an application. Confidentially is provemed by 9 USV. CR 22 and 27 CFR 11.11. It had 41.61. This condection is estimated to late 12 minutes to complete, including pullering proparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of there you require to complete this form and/ore suggestions for reducing this burden, should be sent to the information Officer. U.S. Pleart and Trademark Office. U.S. Department of Commence, P.O. Box 1409, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patterts, P.O. Box 1409, Alexandria, VA 22313-1450.

*Total of 1647

forms are submitted.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether disclosure of these records is required by the Freedom of Information Act.
- A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neoditations.
- A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the
- A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
- A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
- A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- 8. A record from this system of records may be disclosed, as a noutine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspection or an issued patent.
- A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.